DNA methylation biomarkers in biological fluids for early detection of respiratory tract cancer

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 10, 2012, Pages 1723-1731

  Markopoulou, Soultana ^a   Nikolaidis, Georgios ^b   Liloglou, Triantafillos ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Biomarkers; DNA methylation; Lung cancer; Oral cancer

Indexed keywords

BIOLOGICAL MARKER; DNA; METHYLATION SENSITIVE RESTRICTION ENDONUCLEASE; MICRORNA; RESTRICTION ENDONUCLEASE; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ASSAY; BLOOD LEVEL; BRONCHIAL ARTERY; BRONCHOSCOPY; CANCER DIAGNOSIS; CLINICAL LABORATORY; CPG ISLAND; CYTOLOGY; DNA METHYLATION; EARLY DIAGNOSIS; EPIGENETICS; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LUNG LAVAGE; LUNG NON SMALL CELL CANCER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEDICAL TECHNOLOGY; MICROARRAY ANALYSIS; MOUTH CANCER; PATIENT MONITORING; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; RESPIRATORY TRACT CANCER; REVIEW; SALIVA ANALYSIS; SERUM; SMOKING; SPUTUM ANALYSIS; SQUAMOUS CELL CARCINOMA; TISSUE SPECIFICITY; VALIDATION STUDY;

ANIMALS; BASE SEQUENCE; BODY FLUIDS; DNA METHYLATION; EARLY DETECTION OF CANCER; HUMANS; RESPIRATORY TRACT NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867766684     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0124     Document Type: Review

References (80)

1. Ferlay A. GLOBOCAN 2008, Cancer incidence and mortality worldwide. IARC CancerBase No. 10. Lyon: IARC, 2011.
2. McErlean A, Ginsberg MS. Epidemiology of lung cancer. Semin Roentgenol 2011;46:173-7.
3. Conway DI, Hashibe M, Boffetta P, Wunsch-Filho V, Muscat J, La Vecchia C, et al. Enhancing epidemiologic research on head and neck cancer: INHANCE-The international head and neck cancer epidemiology consortium. Oral Oncol 2009;45:743-6.
4. Waddington CH. The epigenotype. Endeavour 1942;1:18-20.
5. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010;31:27-36.
6. Tsai HC, Baylin SB. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res 2011;21:502-17.
7. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010;28:1057-68.
8. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999;99:247-57.
9. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 1998;19:219-20.
10. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16:6-21.
11. Esteller M. Cancer epigenomics: DNA methylomes and histonemodification maps. Nat Rev Genet 2007;8:286-98.
12. Daskalos A, Nikolaidis G, Xinarianos G, Savvari P, Cassidy A, Zakopoulou R, et al. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int J Cancer 2009;124:81-7.
13. Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, et al. Differential methylation of tissue-and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 2009;41:1350-3.
14. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al. The human colon cancer methylome shows similar hypoand hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009;41:178-86.
15. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009;462:315-22.
16. Laurent L, Wong E, Li G, Huynh T, Tsirigos A, Ong CT, et al. Dynamic changes in the human methylome during differentiation. Genome Res 2010;20:320-31.
17. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59.
18. Watt PM, Kumar R, Kees UR. Promoter demethylation accompanies reactivation of the HOX11 proto-oncogene in leukemia. Genes Chromosomes Cancer 2000;29:371-7.
19. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta 2007;1775:138-62.
20. Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985;228:187-90.
21. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007;67:1424-9.
22. Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 2008;68:4123-32.
23. Field JK, Liloglou T, Warrak S, Burger M, Becker E, Berlin K, et al. Methylation discriminators in NSCLC identified by a microarray based approach. Int J Oncol 2005;27:105-11.
24. Ehrich M, Field JK, Liloglou T, Xinarianos G, Oeth P, Nelson MR, et al. Cytosine methylation profiles as a molecular marker in non-small cell lung cancer. Cancer Res 2006;66:10911-8.
25. Verri C, Roz L, Conte D, Liloglou T, Livio A, Vesin A, et al. Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project. Am J Respir Crit Care Med 2009;179:396-401.
26. Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Manegold C, et al. Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer 2007;56:115-23.
27. Kim DS, Cha SI, Lee JH, Lee YM, Choi JE, Kim MJ, et al. Aberrant DNA methylation profiles of non-small cell lung cancers in a Korean population. Lung Cancer 2007;58:1-6.
28. Shivapurkar N, Sherman ME, Stastny V, Echebiri C, Rader JS, Nayar R, et al. Evaluation of candidate methylation markers to detect cervical neoplasia. Gynecol Oncol 2007;107:549-53.
29. Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1511-6.
30. Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier K, et al. The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol 2005;20:645-63.
31. Chen C, Yin N, Yin B, Lu Q. DNA methylation in thoracic neoplasms. Cancer Lett 2011;301:7-16.
32. Marsit CJ, Christensen BC, Houseman EA, Karagas MR, Wrensch MR, Yeh RF, et al. Epigenetic profiling reveals etiologically distinct patterns of DNA methylation in head and neck squamous cell carcinoma. Carcinogenesis 2009;30:416-22.
33. Hasegawa H, Ninomiya M, Honbou T, Hamatsu T, Kudo K, Ushijima C, et al. [A case of long-term survival by combined modality therapy for liver and pulmonary metastasis of rectal cancer]. Gan To Kagaku Ryoho/Cancer Chemother 2011;38:2310-2.
34. Dikshit RP, Gillio-Tos A, Brennan P, De Marco L, Fiano V, Martinez-Penuela JM, et al. Hypermethylation, risk factors, clinical characteristics, and survival in 235 patients with laryngeal and hypopharyngeal cancers. Cancer 2007;110:1745-51.
35. Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, Lowe D, et al. Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br J Cancer 2006;94:561-8.
36. Shaw RJ, Hall GL, Lowe D, Bowers NL, Liloglou T, Field JK, et al. CpG island methylation phenotype (CIMP) in oral cancer: associated with a marked inflammatory response and less aggressive tumour biology. Oral Oncol 2007;43:878-86.
37. Shaw RJ, Hall GL, Woolgar JA, Lowe D, Rogers SN, Field JK, et al. Quantitative methylation analysis of resection margins and lymph nodes in oral squamous cell carcinoma. Br J Oral Maxillofac Surg 2007;45:617-22.
38. Shaw RJ, Omar MM, Rokadiya S, Kogera FA, Lowe D, Hall GL, et al. Cytoglobin is upregulated by tumour hypoxia and silenced by promoter hypermethylation in head and neck cancer. Br J Cancer 2009;101:139-44.
39. Schache AG, Hall G, Woolgar JA, Nikolaidis G, Triantafyllou A, Lowe D, et al. Quantitative promoter methylation differentiates carcinoma ex pleomorphic adenoma from pleomorphic salivary adenoma. Br J Cancer 2010;103:1846-51.
40. Chalitchagorn K, Shuangshoti S, Hourpai N, Kongruttanachok N, Tangkijvanich P, Thong-ngam D, et al. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene 2004;23:8841-6.
41. Poage GM, Houseman EA, Christensen BC, Butler RA, Avissar-Whiting M, McClean MD, et al. Global hypomethylation identifies loci targeted for hypermethylation in head and neck cancer. Clin Cancer Res 2011;17:3579-89.
42. Hall GL, Shaw RJ, Field EA, Rogers SN, Sutton DN, Woolgar JA, et al. p16 Promoter methylation is a potential predictor of malignant transformation in oral epithelial dysplasia. Cancer Epidemiol Biomarkers Prev 2008;17:2174-9.
43. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011;17:330-9.
44. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004;4:707-17.
45. Martin-Subero JI, Esteller M. Profiling epigenetic alterations in disease. Adv Exp Med Biol 2011;711:162-77.
46. Daskalos A, Oleksiewicz U, Filia A, Nikolaidis G, Xinarianos G, Gosney JR, et al. UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer. Cancer 2011;117:1027-37.
47. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc 2007;2:2265-75.
48. Bossuyt PM, Reitsma JB. The STARD initiative. Lancet 2003;361:71.
49. McShane LM, Altman DG, Sauerbrei W. Identification of clinically useful cancer prognostic factors: what are we missing? J Natl Cancer Instit Comment Editorial 2005;97:1023-5.
50. Dobler CC, Crawford AB. Bronchoscopic diagnosis of endoscopically visible lung malignancies: should cytological examinations be carried out routinely? Intern Med J 2009;39:806-11.
51. Van't Westeinde SC, van Klaveren RJ. Screening and early detection of lung cancer. Cancer J 2011;17:3-10.
52. Ahrendt SA, Chow JT, Xu LH, Yang SC, Eisenberger CF, Esteller M, et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999;91:332-9.
53. Kim H, Kwon YM, Kim JS, Lee H, Park JH, Shim YM, et al. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J Clin Oncol 2004;22:2363-70.
54. Topaloglu O, Hoque MO, Tokumaru Y, Lee J, Ratovitski E, Sidransky D, et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 2004;10:2284-8.
55. Schmiemann V, Bocking A, Kazimirek M, Onofre AS, Gabbert HE, Kappes R, et al. Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study. Clin Cancer Res 2005;11:7728-34.
56. Grote HJ. [Aberrant promoter methylation as biomarker for molecular cytological diagnosis of lung cancer]. Verh Dtsch Ges Pathol 2006;90:216-26.
57. van der Drift MA, Prinsen CF, Knuiman GJ, Janssen JP, Dekhuijzen PN, Thunnissen FB. Diagnosing peripheral lung cancer: the additional value of the Ras-association domain family 1A gene methylation and Kirsten rat sarcoma 2 viral oncogene homolog mutation analyses in washings in nondiagnostic bronchoscopy. Chest 2012;141:169-75. Epub 2011 Jun. 23.
58. Hwang SH, Kim KU, Kim JE, Kim HH, Lee MK, Lee CH, et al. Detection of HOXA9 gene methylation in tumor tissues and induced sputum samples from primary lung cancer patients. Clin Chem Lab Med 2011;49:699-704.
59. Yasuda H, Soejima K, Nakayama S, Kawada I, Nakachi I, Yoda S, et al. Bronchoscopic microsampling is a useful complementary diagnostic tool for detecting lung cancer. Lung Cancer 2011;72:32-8.
60. Schmidt B, Liebenberg V, Dietrich D, Schlegel T, Kneip C, Seegebarth A, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer 2010;10:600.
61. Dietrich D, Kneip C, Raji O, Liloglou T, Seegebarth A, Schlegel T, et al. Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int J Oncol 2012;40:825-32.
62. Kneip C, Schmidt B, Seegebarth A, Weickmann S, Fleischhacker M, Liebenberg V, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol 2011;6:1632-8.
63. de Fraipont F, Moro-Sibilot D, Michelland S, Brambilla E, Brambilla C, Favrot MC. Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer? Lung Cancer 2005;50:199-209.
64. Subbalekha K, Pimkhaokham A, Pavasant P, Chindavijak S, Phokaew C, Shuangshoti S, et al. Detection of LINE-1s hypomethylation in oral rinses of oral squamous cell carcinoma patients. Oral Oncol 2009;45:184-91.
65. Pobsook T, Subbalekha K, Sannikorn P, Mutirangura A. Improved measurement of LINE-1 sequence methylation for cancer detection. Clin Chim Acta 2011;412:314-21.
66. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008;68:2094-105.
67. Langevin SM, Stone RA, Bunker CH, Grandis JR, Sobol RW, Taioli E. MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index. Carcinogenesis 2010;31:864-70.
68. Demokan S, Chang X, Chuang A, Mydlarz WK, Kaur J, Huang P, et al. KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses. Int J Cancer 2010;127:2351-9.
69. Pattani KM, Zhang Z, Demokan S, Glazer C, Loyo M, Goodman S, et al. Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila) 2010;3:1093-103.
70. Guerrero-Preston R, Soudry E, Acero J, Orera M, Moreno-Lopez L, Macia-Colon G, et al. NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva. Cancer Prev Res (Phila) 2011;4:1061-72.
71. Carvalho AL, Henrique R, Jeronimo C, Nayak CS, Reddy AN, Hoque MO, et al. Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance. Clin Cancer Res 2011;17:4782-9.
72. Sun W, Zaboli D, Wang H, Liu Y, Arnaoutakis D, Khan T, et al. Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer. Clin Cancer Res 2012;18:1082-91.
73. Lo YM. Circulating nucleic acids in plasma and serum: an overview. Ann N Y Acad Sci 2001;945:1-7.
74. Liu Z, Li W, Lei Z, Zhao J, Chen XF, Liu R, et al. CpG island methylator phenotype involving chromosome 3p confers an increased risk of non-small cell lung cancer. J Thorac Oncol 2010;5:790-7.
75. Vineis P, Chuang SC, Vaissiere T, Cuenin C, Ricceri F, Johansson M, et al. DNA methylation changes associated with cancer risk factors and blood levels of vitamin metabolites in a prospective study. Epigenetics 2011;6:195-201.
76. Wang J, Wang B, Chen X, Bi J. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Carcinogenesis 2011;32:411-6.
77. Ostrow KL, Hoque MO, Loyo M, Brait M, Greenberg A, Siegfried JM, et al. Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res 2010;16:3463-72.
78. Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y, et al. Methylation of multiple genes as a candidate biomarker in nonsmall cell lung cancer. Cancer Lett 2011;303:21-8.
79. Begum S, Brait M, Dasgupta S, Ostrow KL, Zahurak M, Carvalho AL, et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res 2011;17:4494-503.
80. Han W, Wang T, Reilly AA, Keller SM, Spivack SD. Gene promoter methylation assayed in exhaled breath, with differences in smokers and lung cancer patients. Respir Res 2009;10:86.